Innate Pharma SA
IPHA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001598599
No open-market purchases or sales by Innate Pharma SA insiders were filed in the last 90 days; 10 institutions reported holding it in 13F filings for Q2 2026, worth $354.0K in total; no superinvestor holds it.
Other share classesIPHYF
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +1 vs. previous quarter
- 10
- 13F valueReported value at the end of Q2 2026
- $354.0K
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding IPHA, Q2 2026
No superinvestor reported holding IPHA at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Innate Pharma SA insiders from Form 4, newest first.
No open-market purchases or sales by Innate Pharma SA insiders are on file.
Top 10 13F holders, Q2 2026
The largest institutional positions in Innate Pharma SA at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Lion Point Capital, LP | 81,151 | $149.3K | 0.71% | 00.0% | Unchanged |
| Morgan Stanley | 43,524 | $80.1K | 0.00% | 00.0% | Unchanged |
| SmartHarvest Portfolios, LLC | 23,750 | $43.7K | 0.01% | +23,750 | New |
| XTX Topco Ltd | 15,130 | $27.8K | 0.00% | +15,130 | New |
| Citadel Advisors LLC | 12,441 | $22.9K | 0.00% | +12,441 | New |
| Jane Street Group, LLC | 10,310 | $19.0K | 0.00% | −33,055−76.2% | Reduced |
| Rhumbline Advisers | 4,719 | $8.68K | 0.00% | −15−0.3% | Reduced |
| UBS Group AG | 1,363 | $2.51K | 0.00% | +502+58.3% | Added |
| Farther Finance Advisors, LLC | 21 | $38 | 0.00% | +11+110.0% | Added |
| GAMMA Investing LLC | 9 | $17 | 0.00% | −231−96.3% | Reduced |